In Vitro Antifungal Susceptibility of Cryptococcus Gattii

Overview

Journal J Clin Microbiol

Specialty Microbiology

Date 2004 Oct 9

PMID 15472349

Citations 27

Authors

Luciana Trilles

Belkys Fernandez-Torres

Marcia Dos Santos Lazera

Bodo Wanke

Josep Guarro

Affiliations

Soon will be listed here.

Abstract

We have determined the in vitro susceptibilities of 57 strains of Cryptococcus gattii to nine antifungal agents and have compared the MICs for these strains with those for C. neoformans. MICs were determined by a microdilution reference method. Albaconazole and ravuconazole (MICs of 0.04 and 0.05 microg/ml, respectively) showed the best activities. Micafungin showed no activity (MIC of >128 microg/ml). In general, C. gattii was less susceptible than C. neoformans to all drugs tested, with the exception of amphotericin B and flucytosine.

Citing Articles

Advanced approach for antifungal susceptibility and characterization of resistance properties in clinical and environmental isolates of species complex.

Lahiri S, Chandrashekar N Infect Med (Beijing). 2023; 1(3):147-153.

PMID: 38077629 PMC: 10699700. DOI: 10.1016/j.imj.2022.08.006.

Fluconazole Resistance and Virulence in In Vitro Induced-Fluconazole Resistant Strains and in Clinical Fluconazole Resistant Strain of .

Bertout S, Laroche L, Roger F, Krasteva D, Drakulovski P, Bellet V Pathogens. 2023; 12(6).

PMID: 37375448 PMC: 10304499. DOI: 10.3390/pathogens12060758.

Reduced Susceptibility to Azoles in Cryptococcus gattii Correlates with the Substitution R258L in a Substrate Recognition Site of the Lanosterol 14-α-Demethylase.

Carvajal S, Melendres J, Escandon P, Firacative C Microbiol Spectr. 2023; 11(4):e0140323.

PMID: 37341584 PMC: 10434158. DOI: 10.1128/spectrum.01403-23.

Begerowomyces aurantius sp. nov., a novel yeast isolated from koalas' habitat in a Japanese zoological park.

Guo Y, Alshahni M, Satoh K, Tamura T, Alshahni R, Makimura K J Vet Med Sci. 2023; 85(3):271-278.

PMID: 36653148 PMC: 10076191. DOI: 10.1292/jvms.22-0374.

Pulmonary Cryptococcosis.

Howard-Jones A, Sparks R, Pham D, Halliday C, Beardsley J, Chen S J Fungi (Basel). 2022; 8(11).

PMID: 36354923 PMC: 9696922. DOI: 10.3390/jof8111156.

References

Franzot S, Hamdan J . In vitro susceptibilities of clinical and environmental isolates of Cryptococcus neoformans to five antifungal drugs. Antimicrob Agents Chemother. 1996; 40(3):822-4. PMC: 163211. DOI: 10.1128/AAC.40.3.822. View

Speed B, Dunt D . Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin Infect Dis. 1995; 21(1):28-34; discussion 35-6. DOI: 10.1093/clinids/21.1.28. View

Paetznick V, Ghannoum M, Rex J . Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologies. J Clin Microbiol. 1998; 36(10):2817-22. PMC: 105070. DOI: 10.1128/JCM.36.10.2817-2822.1998. View

Tawara S, Ikeda F, Maki K, Morishita Y, Otomo K, Teratani N . In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother. 1999; 44(1):57-62. PMC: 89628. DOI: 10.1128/AAC.44.1.57-62.2000. View

Chen Y, Chang S, Shih C, Hung C, Luhbd K, Pan Y . Clinical features and in vitro susceptibilities of two varieties of Cryptococcus neoformans in Taiwan. Diagn Microbiol Infect Dis. 2000; 36(3):175-83. DOI: 10.1016/s0732-8893(99)00137-6. View

Saag M, Graybill R, Larsen R, Pappas P, Perfect J, Powderly W . Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis. 2000; 30(4):710-8. DOI: 10.1086/313757. View

Yildiran S, Saracli M, Fothergill A, Rinaldi M . In vitro susceptibility of environmental Cryptococcus neoformans variety neoformans isolates from Turkey to six antifungal agents, including SCH56592 and voriconazole. Eur J Clin Microbiol Infect Dis. 2000; 19(4):317-9. DOI: 10.1007/s100960050484. View

Correa M, Oliveira E, Duarte R, Pardal P, Oliveira F, Severo L . [Cryptococcosis in children in the State of Pará, Brazil]. Rev Soc Bras Med Trop. 2000; 32(5):505-8. View

Yamazumi T, Pfaller M, Messer S, Houston A, Hollis R, Jones R . In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans. Antimicrob Agents Chemother. 2000; 44(10):2883-6. PMC: 90171. DOI: 10.1128/AAC.44.10.2883-2886.2000. View

10.

Chen S, Sorrell T, Nimmo G, Speed B, Currie B, Ellis D . Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group. Clin Infect Dis. 2000; 31(2):499-508. DOI: 10.1086/313992. View

11.

Diaz M, Boekhout T, Theelen B, Fell J . Molecular sequence analyses of the intergenic spacer (IGS) associated with rDNA of the two varieties of the pathogenic yeast, Cryptococcus neoformans. Syst Appl Microbiol. 2001; 23(4):535-45. DOI: 10.1016/S0723-2020(00)80028-4. View

12.

Sorrell T . Cryptococcus neoformans variety gattii. Med Mycol. 2001; 39(2):155-68. View

13.

Calvo B, Colombo A, Fischman O, Santiago A, Thompson L, Lazera M . Antifungal susceptibilities, varieties, and electrophoretic karyotypes of clinical isolates of Cryptococcus neoformans from Brazil, Chile, and Venezuela. J Clin Microbiol. 2001; 39(6):2348-50. PMC: 88143. DOI: 10.1128/JCM.39.6.2348-2350.2001. View

14.

Pfaller M, Messer S, Hollis R, Jones R . In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob Agents Chemother. 2001; 45(10):2862-4. PMC: 90743. DOI: 10.1128/AAC.45.10.2862-2864.2001. View

15.

Espinel-Ingroff A, Fothergill A, Peter J, Rinaldi M, Walsh T . Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study. J Clin Microbiol. 2002; 40(9):3204-8. PMC: 130733. DOI: 10.1128/JCM.40.9.3204-3208.2002. View

16.

Yildiran S, Fothergill A, Sutton D, Rinaldi M . In vitro susceptibilities of cerebrospinal fluid isolates of Cryptococcus neoformans collected during a ten-year period against fluconazole, voriconazole and posaconazole (SCH56592). Mycoses. 2002; 45(9-10):378-83. DOI: 10.1046/j.1439-0507.2002.00765.x. View

17.

Nishikawa M, Lazera M, Barbosa G, Trilles L, Balassiano B, Macedo R . Serotyping of 467 Cryptococcus neoformans isolates from clinical and environmental sources in Brazil: analysis of host and regional patterns. J Clin Microbiol. 2003; 41(1):73-7. PMC: 149604. DOI: 10.1128/JCM.41.1.73-77.2003. View

18.

Maxwell M, Messer S, Hollis R, Boyken L, Tendolkar S, Diekema D . Evaluation of Etest method for determining fluconazole and voriconazole MICs for 279 clinical isolates of Candida species infrequently isolated from blood. J Clin Microbiol. 2003; 41(3):1087-90. PMC: 150324. DOI: 10.1128/JCM.41.3.1087-1090.2003. View

19.

Moraes E, Primola N, Hamdan J . Antifungal susceptibility of clinical and environmental isolates of Cryptococcus neoformans to four antifungal drugs determined by two techniques. Mycoses. 2003; 46(5-6):164-8. DOI: 10.1046/j.1439-0507.2003.00872.x. View

20.

Kwon-Chung K, Polacheck I, Bennett J . Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C). J Clin Microbiol. 1982; 15(3):535-7. PMC: 272134. DOI: 10.1128/jcm.15.3.535-537.1982. View